Comparative Pharmacology
Head-to-head clinical analysis: CHLORAMPHENICOL SODIUM SUCCINATE versus FORBAXIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CHLORAMPHENICOL SODIUM SUCCINATE versus FORBAXIN.
CHLORAMPHENICOL SODIUM SUCCINATE vs FORBAXIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Reversibly binds to the 50S ribosomal subunit, inhibiting peptidyl transferase activity and blocking protein synthesis in bacteria.
FORBAXIN is a prodrug of the active moiety cefditoren, a cephalosporin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), leading to cell lysis and death.
Intravenous, 50 mg/kg/day divided every 6 hours; maximum 4 g/day.
IV: 500 mg every 12 hours, infused over 30 minutes.
None Documented
None Documented
Terminal elimination half-life is approximately 1.5-3.5 hours in adults with normal renal and hepatic function. In neonates (first 2 weeks of life), half-life is prolonged to 10-24 hours due to immature hepatic conjugation. In patients with severe hepatic impairment, half-life may exceed 12 hours, necessitating dose adjustment.
8-12 hours; prolonged in renal impairment (up to 24 hours in severe cases)
Approximately 80-90% of the dose is excreted renally as unchanged drug and as the inactive chloramphenicol base (formed by hydrolysis in the liver and kidneys). Biliary excretion accounts for about 5-10%, with some enterohepatic circulation. Fecal excretion is negligible (<2%).
Renal (60-70% unchanged), biliary/fecal (20-30%)
Category D/X
Category C
Antibiotic
Antibiotic